LEO Pharma’s innovation engine is fueled by a global R&D organisation with more than 700 scientists and specialists. Together with business development acquistions and partnerships, we have built a strong pipeline focused on dermatology covering several indications. We are expanding our internal innovation and external partnerships to bring life-changing medicines to people with skin conditions.


Our pipeline includes:

  • a novel pan JAK inhibitor for non-steroidal topical treatment of inflammatory skin diseases (phase II)
  • a novel small molecule compound for topical treatment of actinic keratosis (phase III)
  • a novel oral bio-available PDE4 inhibitor for psoriasis (phase II)
  • an IL-13 antibody for systemic treatment of atopic dermatitis (phase III)
  • an IL-17R antibody for systemic treatment of moderate-to-severe psoriasis (post phase III).

In addition, we explore opportunities to make treatment easier for patients through innovations within medical device technologies and digital solutions and services.

Visit our global site to read more about our pipeline.

Cookies on this site

LEO Laboratories Limited uses cookies to give you the best experience online and to provide anonymised, aggregated site usage data. You can find out what cookies we use, what they do and how you can disable them in our Cookie Policy. By browsing our sites, you consent to the use of cookies. If you want to know more about our cookie policy and how to avoid and delete cookies click here. By continuing to browse this site, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.